drugset / Trial / NCT07491172
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
Timeline
- Start
- 2024-06-21
- Primary completion
- 2027-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTX310 | CRISPR / gene editing | — | Intravenous |